Abstract
Purpose. The authors investigated the use of dapiprazole, an alpha-adrenergic blocking agent, in preventing pigment release and IOP increase after exercise in patients affected with PDS. Methods. Three young myopic males (31, 34 and 35 years old) affected with pigmentary dispersion syndrome performed 30 minutes of jogging on a computerized treadmill. Telemetric heartbeat measurement was performed to obtain constant pulse rate training. Computerized tonography and IOP measurement were performed 10 minutes after the exercise. After one month the patients repeated the same exercise after pre-treatment with dapiprazole 0.5% eyedrops (one drop 30, 20 and 10 minutes before the exercise). Ten minutes after the exercise IOP measurements and computerized tonography were repeated. Results. After 30 minutes of exercise IOP measurements showed values ranging from 19 to 45 mmHg (mean 30.33; SD 8.73). Computerized tonography C values after exercise ranged from 0.04 to 0.16 (mean 0.09; SD 0.04). After pre-treatment with dapiprazole 0.5% eyedrops, IOP values ranged from 18 to 28 mmHg (mean 23.33; SD 3.44) and tonography C values ranged from 0.10 to 0.20 (mean 0.14; SD 0.03). Conclusions. The study supports the concept that exercise-induced pigment release temporarily obstructs the acqueous outflow channels, causing IOP increase in some patients with PDS. Pre-treatment with dapiprazole was useful in reducing IOP spikes and in increasing tonographic total outflow facility after exercise. The absence of induced myopia and the lack of dangerous vitreoretinal tractions on retinal periphery make dapiprazole a safe method to reduce exercise-induced pigment dispersion.
Similar content being viewed by others
References
Sugar, HS, Barbour, FA. Pigmentary glaucoma: a rare clinical entity. Am J Ophthalmol 1949; 32: 90–2.
Bick, MW. Pigmentary glaucoma in females. Arch Ophthalmol 1957; 58: 483–94.
Scheie, HG, Fleischhauer, HW. Idiopatic atrophy of the epithelial layers of the iris and ciliary body: a clinical study. Arch Ophthalmol 1958; 59: 216–28.
Sugar, HS. Pigmentary glaucoma: a 25-year review. Am J Ophthalmol 1966; 62: 499–507.
Lichter, PR, Shaffer, RN. Diagnostic and prognostic signs in pigmentary glaucoma. Trans Am Acad Ophthalmol Otolaryngol 1970; 74: 984–98.
Campbell, DG. Pigmentary dispersion and glaucoma: a new theory. Arch Ophthalmol 1970; 97: 1667–72.
Schenker, HI, Luntz, MH, Kels, B, Podos, SM. Exercise-induced increase in intraocular pressure in the pigmentary dispersion syndrome. Am J Ophthalmol 1980; 89: 598–600.
Epstein, DL, Boger III, WP, Morton Grant, W. Phenylephrine provocative testing in the pigmentary dispersion syndrome. Am J Ophthalmol 1978; 85: 43–50.
Haynes, WL, Tim Johnson, A, Alward, WLM. Inhibition of exercise-induced pigment dispersion in a patient with the pigmentary dispersion syndrome. Am J Ophthalmol 1990; 109: 601–2.
Haynes, WL, Alward, WLM, Tello, C, Liebmann, JM, Ritch, R. Incomplete elimination of exercise-induced pigment dispersion by laser iridotomy in pigment dispersion syndrome. Ophthalmic Surg Lasers 1995; 26: 484–6.
Haynes, WL, Tim Johnson, A, Alward, WLM. Effects of jogging exercise on patients with the pigmentary dispersion syndrome and pigmentary glaucoma. Ophthalmology 1992; 99: 1096–103.
Jensen, PK, Nissen, O, Kessing, SV. Exercise and reversed pupillary block in pigmentary glaucoma. Am J Ophthalmol 1995; 120: 110–2.
Ritch, R. Pigmentary glaucoma: a self limited entity? Ann Ophthalmol 1983; 15: 115–6.
Scheie, HG, Cameron, JD. Pigment dispersion syndrome: a clinical study. Br J Ophthalmol 1981; 65: 264–9.
Weseley, P, Liebmann, J, Walsh, JB, Ritch, R. Lattice degeneration of the retina and the pigment dispersion syndrome. Am J Ophthalmol 1992; 114: 539–43.
Speakman, JS. Pigmentary dispersion. Br J Ophthalmol 1981; 65: 249–51.
Gallenga, PE, Mastropasqua, L. Dapiprazole in pigmentary glaucoma. New Trends In Ophthalmol 1989; 3: 193–6.
Reibaldi, A. A new alpha-blocking agent. Glaucoma 1984; 6: 255–7.
Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma. Ophthalmic Surg Lasers. In press.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mastropasqua, L., Carpineto, P., Ciancaglini, M. et al. The effectiveness of dapiprazole in preventing exercise-induced IOP increase in patients with pigmentary dispersion syndrome. Int Ophthalmol 19, 359–362 (1995). https://doi.org/10.1007/BF00130855
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00130855